ACVR2A and chronic kidney disease: The potential therapeutic effects of modulation of ActRIIA signaling have been further studied by Williams et al., who tested RAP-011 treatment in a non-diabetic mice model of Alport syndrome, characterized by progressive CKD and CKD-MBD, presenting with renal osteodystrophy, vascular calcification, cardiac hypertrophy, and hyperparathyroidism.